Metabolomics-Microbiome Crosstalk in the Breast Cancer Microenvironment
Abstract
:1. Introduction
2. Microbiome: An Overview
3. Methods for Studying the Microbiota
4. Breast Tissue Microbiome
5. Metabolomics for Studying Breast Cancer
6. Interaction between Microbiome and Metabolomics in Breast Cancer
7. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Alqahtani, W.S.; Almufareh, N.A.; Domiaty, D.M.; Albasher, G.; Alduwish, M.A.; Alkhalaf, H.; Almuzzaini, B.; AL-marshidy, S.S.; Alfraihi, R.; Elasbali, A.M. Epidemiology of cancer in Saudi Arabia thru 2010–2019: A systematic review with constrained meta-analysis. AIMS Public Health 2020, 7, 679. [Google Scholar] [PubMed]
- Xuan, C.; Shamonki, J.M.; Chung, A.; DiNome, M.L.; Chung, M.; Sieling, P.A.; Lee, D.J. Microbial Dysbiosis Is Associated with Human Breast Cancer. PLoS ONE 2014, 9, e83744. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Parida, S.; Sharma, D. Microbial Alterations and Risk Factors of Breast Cancer: Connections and Mechanistic Insights. Cells 2020, 9, 1091. [Google Scholar] [CrossRef] [PubMed]
- Society, A.C. Cancer Facts & Figures; American Cancer Society: Atlanta, CA, USA, 2016; pp. 1–72. [Google Scholar]
- Yousef, A.J.A. Male Breast Cancer: Epidemiology and Risk Factors. Semin. Oncol. 2017, 44, 267–272. [Google Scholar] [CrossRef]
- Lautrup, M.D.; Thorup, S.S.; Jensen, V.; Bokmand, S.; Haugaard, K.; Hoejris, I.; Jylling, A.-M.B.; Joernsgaard, H.; Lelkaitis, G.; Oldenburg, M.H. Male breast cancer: A nation-wide population-based comparison with female breast cancer. Acta Oncol. 2018, 57, 613–621. [Google Scholar] [CrossRef] [Green Version]
- Ugnat, A.; Xie, L.; Morriss, J.; Semenciw, R.; Mao, Y. Survival of women with breast cancer in Ottawa, Canada: Variation with age, stage, histology, grade and treatment. Br. J. Cancer 2004, 90, 1138–1143. [Google Scholar] [CrossRef] [Green Version]
- Sinn, H.P.; Kreipe, H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care 2013, 8, 149–154. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tan, P.H.; Ellis, I.; Allison, K.; Brogi, E.; Fox, S.B.; Lakhani, S.; Lazar, A.J.; Morris, E.A.; Sahin, A.; Salgado, R. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020, 77, 181–185. [Google Scholar] [CrossRef] [PubMed]
- Akslen, L.A.; Watnick, R.S. Biomarkers of the Tumor Microenvironment; Springer: Heidelberg, Germany, 2017; pp. 1–2. [Google Scholar]
- Sazeides, C.; Le, A. Metabolic Relationship between Cancer-Associated Fibroblasts and Cancer Cells; Springer: Cham, Switzerland, 2018; pp. 149–165. [Google Scholar]
- Lopes-Bastos, B.M.; Jiang, W.G.; Cai, J. Tumour–endothelial cell communications: Important and indispensable mediators of tumour angiogenesis. Anticancer Res. 2016, 36, 1119–1126. [Google Scholar] [PubMed]
- Wang, B.; Xi, C.; Liu, M.; Sun, H.; Liu, S.; Song, L.; Kang, H. Breast fibroblasts in both cancer and normal tissues induce phenotypic transformation of breast cancer stem cells: A preliminary study. PeerJ 2018, 6, e4805. [Google Scholar] [CrossRef]
- Aboussekhra, A. Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int. J. Dev. Biol. 2011, 55, 841–849. [Google Scholar] [CrossRef] [Green Version]
- Yamashita, M.; Ogawa, T.; Zhang, X.; Hanamura, N.; Kashikura, Y.; Takamura, M.; Yoneda, M.; Shiraishi, T. Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer 2012, 19, 170–176. [Google Scholar] [CrossRef]
- Wang, N.; Sun, T.; Xu, J. Tumor-related Microbiome in the Breast Microenvironment and Breast Cancer. J. Cancer 2021, 12, 4841–4848. [Google Scholar] [CrossRef] [PubMed]
- Kovács, T.; Mikó, E.; Ujlaki, G.; Sári, Z.; Bai, P. Tumor Microenvironment; Springer: Heidelberg, Germany, 2020; pp. 137–153. [Google Scholar]
- Wong-Rolle, A.; Wei, H.K.; Zhao, C.; Jin, C. Unexpected guests in the tumor microenvironment: Microbiome in cancer. Protein Cell 2021, 12, 426–435. [Google Scholar] [CrossRef] [PubMed]
- Zheng, D.; Liwinski, T.; Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020, 30, 492–506. [Google Scholar] [CrossRef] [PubMed]
- Urbaniak, C.; Kenderian, S.S. The microbiota of breast tissue and its association with breast cancer. Appl. Environ. Microbiol. 2016, 82, 5039–5048. [Google Scholar] [CrossRef] [Green Version]
- Mani, S. Microbiota and Breast Cancer. Prog. Mol. Biol. Transl. Sci. 2017, 151, 217–229. [Google Scholar]
- Nallu, A.; Sharma, S.; Ramezani, A.; Muralidharan, J.; Raj, D. Gut microbiome in chronic kidney disease: Challenges and opportunities. Trans. Res. 2017, 179, 24–37. [Google Scholar] [CrossRef] [Green Version]
- Kostic, A.D.; Xavier, R.J.; Gevers, D. The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology 2014, 146, 1489–1499. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arnold, W.M.; Hill, E.S.; Fei, N.; Yee, A.L.; Garcia, M.S.; Cralle, L.E.; Gilbert, J.A. The Human Microbiome in Health and Disease. Genomic Applications in Pathology; Springer: Berlin/Heidelberg, Germany, 2019; pp. 607–618. [Google Scholar]
- Gilbert, J.A.; Blaser, M.J.; Caporaso, J.G.; Jansson, J.K.; Lynch, S.V.; Knight, R. Current understanding of the human microbiome. Nat. Med. 2018, 24, 392–400. [Google Scholar] [CrossRef]
- Pacifici, R. Distant Immune and Microbiome Regulation. Reference Module in Biomedical Sciences; Elsevier: Amsterdam, The Netherlands, 2019. [Google Scholar]
- Yu, M.; Jia, H.; Zhou, C.; Yang, Y.; Zhao, Y.; Yang, M.; Zou, Z. Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics. J. Pharm. Biomed. Anal. 2017, 138, 231–239. [Google Scholar] [CrossRef] [PubMed]
- Shaffer, M.; Armstrong, A.J.S.; Phelan, V.V.; Reisdorph, N.; Lozupone, C.A. Microbiome and metabolome data integration provides insight into health and disease. Trans. Res. 2017, 189, 51–64. [Google Scholar] [CrossRef]
- Zhu, J.; Liao, M.; Yao, Z.; Liang, W.; Li, Q.; Liu, J.; Yang, H.; Ji, Y.; Wei, W.; Tan, A.; et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome 2018, 6, 136. [Google Scholar] [CrossRef] [Green Version]
- Chadha, J.; Nandi, D.; Atri, Y.; Nag, A. Significance of Human Microbiome in Breast Cancer: Tale of an invisible and an invincible. Semin. Cancer Biol. 2020, 70, 112–127. [Google Scholar] [CrossRef]
- Eslami, S.Z.; Majidzadeh, A.K.; Halvaei, S.; Babapirali, F.; Esmaeili, R. Microbiome and Breast Cancer: New Role for an Ancient Population. Front. Oncol. 2020, 10, 120. [Google Scholar] [CrossRef] [Green Version]
- Chen, J.; Douglass, J.; Prasath, V.; Neace, M.; Atrchian, S.; Manjili, M.H.; Shokouhi, S.; Habibi, M. The microbiome and breast cancer: A review. Breast Cancer Res Treat. 2019, 178, 493–496. [Google Scholar] [CrossRef]
- Mikó, E.; Kovács, T.; Sebő, É.; Tóth, J.; Csonka, T.; Ujlaki, G.; Sipos, A.; Szabó, J.; Méhes, G.; Bai, P. Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. Cells 2019, 8, 293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.; Altemus, J.; Niazi, F.; Green, H.; Calhoun, B.C.; Sturgis, C.; Grobmyer, S.R.; Eng, C. Breast tissue, oral and urinary microbiomes in breast cancer. Oncotarget 2017, 8, 88122. [Google Scholar] [CrossRef] [Green Version]
- Ahn, J.; Yang, L.; Paster, B.J.; Ganly, I.; Morris, L.; Pei, Z.; Hayes, R.B. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. PLoS ONE 2011, 6, e22788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lasken, R.S.; McLean, J.S. Recent advances in genomic DNA sequencing of microbial species from single cells. Nat. Rev. Genet. 2014, 15, 577–584. [Google Scholar] [CrossRef]
- Lee, Y.-J.; Nostrand, J.D.; Tu, Q.; Lu, Z.; Cheng, L.; Yuan, T.; Deng, Y.; Carter, M.Q.; He, Z.; Wu, L.; et al. The PathoChip, a functional gene array for assessing pathogenic properties of diverse microbial communities. ISME J. 2013, 7, 1974–1984. [Google Scholar] [CrossRef] [Green Version]
- Brun, P. The profiles of dysbiotic microbial communities. AIMS Microbiol. 2019, 5, 87. [Google Scholar] [CrossRef]
- Wang, Q.; Garrity, G.M.; Tiedje, J.M.; Cole, J.R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 2007, 73, 5261–5267. [Google Scholar] [CrossRef] [Green Version]
- Hiergeist, A.; Reischl, U.; Gessner, A. Multicenter quality assessment of 16S ribosomal DNA-sequencing for microbiome analyses reveals high inter-center variability. Int. J. Med. Microbiol. 2016, 306, 334–342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, Y.-W.; Chen, M.-K.; Yang, B.-Y.; Huang, X.-J.; Zhang, X.-R.; He, L.-Q. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in mouse feces. Appl. Environ. Microbiol. 2015, 81, 6749–6756. [Google Scholar] [CrossRef] [Green Version]
- Jovel, J.; Patterson, J.; Wang, W.; Hotte, N.; O’Keefe, S.; Mitchel, T.; Perry, T.; Kao, D.; Mason, A.L.; Madsen, K.L.; et al. Characterization of the gut microbiome using 16S or shotgun metagenomics. Front. Microbiol. 2016, 7, 459. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xavier, J.B.; Young, V.B.; Skufca, J.; Ginty, F.; Testerman, T.; Pearson, A.T.; Macklin, P.; Mitchell, A.; Shmulevich, I.; Xie, L.; et al. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer 2020, 6, 192–204. [Google Scholar] [CrossRef] [Green Version]
- Fernández, M.F.; Reina-Pérez, I.; Astorga, J.M.; Rodríguez-Carrillo, A.; Plaza-Díaz, J.; Fontana, L. Breast Cancer and Its Relationship with the Microbiota. Int. J. Environ. Res. Public Health 2018, 15, 1747. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Costantini, L.; Magno, S.; Albanese, D.; Donati, C.; Molinari, R.; Filippone, A.; Masetti, R.; Merendino, N. Characterization of human breast tissue microbiota from core needle biopsies through the analysis of multi hypervariable 16S-rRNA gene regions. Sci. Rep. 2018, 8, 16893. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thompson, K.J.; Ingle, J.N.; Tang, X.; Chia, N.; Jeraldo, P.R.; Walther-Antonio, M.R.; Kandimalla, K.K.; Johnson, S.; Yao, J.Z.; Harrington, S.C.; et al. A comprehensive analysis of breast cancer microbiota and host gene expression. PLoS ONE 2017, 12, e0188873. [Google Scholar] [CrossRef]
- Nejman, D.; Livyatan, I.; Fuks, G.; Gavert, N.; Zwang, Y.; Geller, L.T.; Rotter-Maskowitz, A.; Weiser, R.; Mallel, G.; Gigi, E.; et al. The human tumor microbiome is composed of tumor type–specific intracellular bacteria. Science. 2020, 368, 973–980. [Google Scholar] [CrossRef]
- Urbaniak, C.; Cummins, J.; Brackstone, M.; Macklaim, J.M.; Gloor, G.B.; Baban, C.K.; Scott, L.; O’Hanlon, D.M.; Burton, J.P.; Francis, K.P.; et al. Microbiota of Human Breast Tissue. Appl. Environ. Microbiol. 2014, 80, 3007–3014. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Banerjee, S.; Tian, T.; Wei, Z.; Shih, N.; Feldman, M.D.; Peck, K.N.; DeMichele, A.M.; Alwine, J.C.; Robertson, E.S. Distinct Microbial Signatures Associated with Different Breast Cancer Types. Front. Microbiol. 2018, 9, 951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jacob, M.; Lopata, A.L.; Dasouki, M.; Abdel Rahman, A.M. Metabolomics toward Personalized Medicine. Mass Spectrom Rev. 2019, 38, 221–238. [Google Scholar] [CrossRef]
- Jacob, M.; Malkawi, A.; Albast, N.; Al Bougha, S.; Lopata, A.; Dasouki, M.; Rahman, A.A.A. A targeted metabolomics approach for clinical diagnosis of inborn errors of metabolism. Anal. Chim. Acta 2018, 1025, 141–153. [Google Scholar] [CrossRef]
- Brauer, H.A.; Makowski, L.; Hoadley, K.A.; Casbas-Hernandez, P.; Lang, L.J.; Romàn-Pèrez, E.; D’Arcy, M.; Freemerman, A.J.; Perou, C.M.; Troester, M.A. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin. Cancer Res. 2013, 19, 571–585. [Google Scholar] [CrossRef] [Green Version]
- Gu, X.; Al Dubayee, M.; Alshahrani, A.; Masood, A.; Benabdelkamel, H.; Zahra, M.; Li, L.; Rahman, A.A.A.; Aljada, A. Distinctive Metabolomics Patterns Associated With Insulin Resistance and Type 2 Diabetes Mellitus. Front. Mol. Biosci. 2020, 7, 609806. [Google Scholar] [CrossRef]
- Aleidi, S.M.; Dahabiyeh, L.A.; Gu, X.; Al Dubayee, M.; Alshahrani, A.; Benabdelkamel, H.; Mujammami, M.; Li, L.; Aljada, A.; Rahman, A.M.A. Obesity Connected Metabolic Changes in Type 2 Diabetic Patients Treated With Metformin. Front. Pharmacol. 2021, 11, 616157. [Google Scholar] [CrossRef]
- Budczies, J.; Brockmöller, S.F.; Müller, B.M.; Barupal, D.K.; Richter-Ehrenstein, C.; Kleine-Tebbe, A.; Griffin, J.L.; Dietel, M.; Denkert, C.; Fiehn, O.; et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: Alterations in glutamine and beta-alanine metabolism. J. Proteom. 2013, 94, 279–288. [Google Scholar] [CrossRef]
- Cardoso, M.R.; Santos, J.C.; Ribeiro, M.L.; Talarico, M.C.R.; Viana, L.R.; Derchain, S.F.M. A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response. Int. J. Mol. Sci. 2018, 19, 617. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaushik, A.K.; DeBerardinis, R.J. Applications of metabolomics to study cancer metabolism. Biochim. Biophys. Acta Rev. Cancer 2018, 1870, 2–14. [Google Scholar] [CrossRef]
- Tan, J.; Le, A. Breast Cancer Metabolism. In The Heterogeneity of Cancer Metabolism; Le, A., Ed.; Springer International Publishing: Cham, Switzerland, 2018; pp. 83–93. [Google Scholar]
- Günther, U.L. Metabolomics Biomarkers for Breast Cancer. Pathobiology 2015, 82, 153–165. [Google Scholar] [CrossRef]
- More, T.H.; Roy, C.S.; Christie, J.; Taunk, K.; Mane, A.; Santra, M.K.; Chaudhury, K.; Rapole, S. Metabolomic alterations in invasive ductal carcinoma of breast: A comprehensive metabolomic study using tissue and serum samples. Oncotarget 2017, 9, 2678–2696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tayyari, F.; Gowda, G.N.; Olopade, O.F.; Berg, R.; Yang, H.H.; Lee, M.; Ngwa, W.; Mittal, S.; Raftery, D.; Mohammed, S. Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. Oncotarget 2018, 9, 11677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Budczies, J.; Denkert, C.; Müller, B.M.; Brockmöller, S.F.; Klauschen, F.; Györffy, B.; Dietel, M.; Richter-Ehrenstein, C.; Marten, U.; Salek, R.M.; et al. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue—A GC-TOFMS based metabolomics study. BMC Genom. 2012, 13, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Warburg, O. On the origin of cancer cells. Science 1956, 123, 309–314. [Google Scholar] [CrossRef] [PubMed]
- Martinez-Outschoorn, U.E.; Balliet, R.; Lin, Z.; Whitaker-Menezes, D.; Birbe, R.C.; Bombonati, A.; Pavlides, S.; Lamb, R.; Sneddon, S.; Howell, A.; et al. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: Implications for breast cancer prevention with antioxidant therapies. Cell Cycle 2012, 11, 4402–4413. [Google Scholar] [CrossRef] [Green Version]
- Valvona, C.J.; Fillmore, H.L.; Nunn, P.B.; Pilkington, G.J. The regulation and function of lactate dehydrogenase a: Therapeutic potential in brain tumor. Brain Pathol. 2016, 26, 3–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dennison, J.B.; Molina, J.R.; Mitra, S.; González-Angulo, A.M.; Balko, J.M.; Kuba, M.G.; Sanders, M.E.; Pinto, J.A.; Gómez, H.L.; Arteaga, C.L.; et al. Lactate dehydrogenase B: A metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin. Cancer Res. 2013, 19, 3703–3713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McCleland, M.L.; Adler, A.S.; Shang, Y.; Hunsaker, T.; Truong, T.; Peterson, D.; Torres, E.; Li, L.; Haley, B.; Stephan, J.P.; et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res. 2012, 72, 5812–5823. [Google Scholar] [CrossRef] [Green Version]
- Brown, N.J.; Higham, S.E.; Perunovic, B.; Arafa, M.; Balasubramanian, S.; Rehman, I. Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS ONE 2013, 8, e57697. [Google Scholar] [CrossRef] [Green Version]
- Rattigan, Y.I.; Patel, B.B.; Ackerstaff, E.; Sukenick, G.; Koutcher, J.A.; Glod, J.W.; Banerjee, D. Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp. Cell Res. 2012, 318, 326–335. [Google Scholar] [CrossRef] [Green Version]
- Lane, A.N.; Tan, J.; Wang, Y.; Yan, J.; Higashi, R.M.; Fan, T.W.-M. Probing the metabolic phenotype of breast cancer cells by multiple tracer stable isotope resolved metabolomics. Metab. Eng. 2017, 43, 125–136. [Google Scholar] [CrossRef] [Green Version]
- Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A.L.; Kafri, R.; Kirschner, M.W.; Clish, C.B.; Mootha, V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336, 1040–1044. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xie, G.; Zhou, B.; Zhao, A.; Qiu, Y.; Zhao, X.; Garmire, L.; Shvetsov, Y.B.; Yu, H.; Yen, Y.; Jia, W. Lowered circulating aspartate is a metabolic feature of human breast cancer. Oncotarget 2015, 6, 33369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Torata, N.; Kubo, M.; Miura, D.; Ohuchida, K.; Mizuuchi, Y.; Fujimura, Y.; Hayakawa, E.; Kai, M.; Oda, Y.; Mizumoto, K.; et al. Visualizing energy charge in breast carcinoma tissues by MALDI mass-spectrometry imaging profiles of low-molecular-weight metabolites. Anticancer Res. 2018, 38, 4267–4272. [Google Scholar] [CrossRef]
- Fernandez, L.P.; Cedron, M.G.; Molina, A.R. Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. Front. Oncol. 2020, 10, 577420. [Google Scholar] [CrossRef]
- Brockmöller, S.F.; Bucher, E.; Müller, B.M.; Budczies, J.; Hilvo, M.; Griffin, J.L.; Orešič, M.; Kallioniemi, O.; Iljin, K.; Loibl, S.; et al. Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer—Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling. J. Proteome Res. 2012, 11, 850–860. [Google Scholar] [CrossRef]
- Hilvo, M.; Denkert, C.; Lehtinen, L.; Müller, B.; Brockmöller, S.; Seppänen-Laakso, T.; Budczies, J.; Bucher, E.; Yetukuri, L.; Castillo, S.; et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 2011, 71, 3236–3245. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mimmi, M.C.; Finato, N.; Pizzolato, G.; Beltrami, C.A.; Fogolari, F.; Corazza, A.; Esposito, G. Absolute quantification of choline-related biomarkers in breast cancer biopsies by liquid chromatography electrospray ionization mass spectrometry. Anal. Cell. Pathol. 2013, 36, 71–83. [Google Scholar] [CrossRef]
- Bathen, T.F.; Geurts, B.; Sitter, B.; Fjøsne, H.E.; Lundgren, S.; Buydens, L.M.; Gribbestad, I.S.; Postma, G.; Giskeødegård, G.F. Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery. PLoS ONE 2013, 8, e61578. [Google Scholar] [CrossRef] [Green Version]
- Rossi, T.; Vergara, D.; Fanini, F.; Maffia, M.; Bravaccini, S.; Pirini, F. Microbiota-derived metabolites in tumor progression and metastasis. Int. J. Mol. Sci. 2020, 21, 5786. [Google Scholar] [CrossRef]
- Wiebe, J.P.; Muzia, D.; Hu, J.; Szwajcer, D.; Hill, S.A.; Seachrist, J.L. The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 2000, 60, 936–943. [Google Scholar] [PubMed]
- Flores, R.; Shi, J.; Fuhrman, B.; Xu, X.; Veenstra, T.D.; Gail, M.H.; Gajer, P.; Ravel, J.; Goedert, J.J. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: A cross-sectional study. J. Trans. Med. 2012, 10, 253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sui, Y.; Wu, J.; Chen, J. The Role of Gut Microbial β-Glucuronidase in Estrogen Reactivation and Breast Cancer. Front. Cell Dev. Biol. 2021, 9, 631552. [Google Scholar] [CrossRef] [PubMed]
- Ma, J.; Sun, L.; Liu, Y.; Ren, H.; Shen, Y.; Bi, F.; Zhnag, T.; Wang, X. Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer. BMC Microbiol. 2020, 20, 1–19. [Google Scholar] [CrossRef] [PubMed]
- Mikó, E.; Vida, A.; Kovács, T.; Ujlaki, G.; Trencsényi, G.; Márton, J.; Sári, Z.; Kovács, P.; Boratkó, A.; Hujber, Z.; et al. Lithocholic acid, a bacterial metabolite reduces breast cancer cell proliferation and aggressiveness. Biochim. Biophys. Acta Bioenergy 2018, 1859, 958–974. [Google Scholar] [CrossRef] [PubMed]
- Sári, Z.; Mikó, E.; Kovács, T.; Jankó, L.; Csonka, T.; Lente, G.; Sebő, É.; Tóth, J.; Tóth, D.; Árkosy, P.; et al. Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress. Cancers 2020, 12, 2411. [Google Scholar] [CrossRef] [PubMed]
- Kovács, T.; Mikó, E.; Vida, A.; Sebő, É.; Toth, J.; Csonka, T.; Boratkó, A.; Ujlaki, G.; Lente, G.; Kovács, P.; et al. Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. Sci. Rep. 2019, 9, 1300. [Google Scholar] [CrossRef] [Green Version]
Sample Type and Size | Method | Variable Region | Changes to the Microbiome | Ref. | |||||
---|---|---|---|---|---|---|---|---|---|
Healthy | Benign | Cancer | Adjacent | Healthy Patients | Cancer Patients | Adjacent | |||
20 | 20 | NGS | V4 | ↑ Methylobacterium radiotolerans | ↑ Sphingomonas yanoikuyae | [2] | |||
24 | 17 | 22 | NGS | V3–V4 | ↓ Methylobacterium | [34] | |||
23 | 13 | 45 | NGS | V6 | ↑ Prevotella, Lactococcus, Streptococcus, Corynebacterium, and Micrococcus | ↑ Bacillus, Staphylococcus, Enterobacteriaceae, Comamondaceae, and Bacteroidetes. | [20] | ||
668 | 72 | NGS | V3–V5 | ↑ Mycobacterium fortuitum and Mycobacterium phlei | [46] | ||||
5, Canadians | 11 | 27 | NGS | V6 | The most abundant taxa in the Canadian samples were: Bacillus (11.4%), Acinetobacter (10.0%), Enterobacteriaceae (8.3%), Pseudomonas (6.5%), Staphylococcus (6.5%), Propionibacterium (5.8%), Comamonadaceae (5.7%), Gammaproteobacteria (5.0%), and Prevotella (5.0%). | [48] | |||
5, Irish | 33 | The most abundant taxa in the Irish samples were: Enterobacteriaceae (30.8%), Staphylococcus (12.7%), Listeria welshimeri (12.1%), Propionibacterium (10.1%), and Pseudomonas (5.3%). ↑ Escherichia coli | [48] | ||||||
20 | 50, BRER 34, BRHR 24, BRTP 40, BRTN | PathChip array | Unique and common microbial signatures in the major breast cancer types are summarized in Table 1 in (51) All four breast cancer types had dominant signatures for Proteobacteria followed by Firmicutes. Actinomyces signatures were also detected in each breast cancer types. | [49] | |||||
9, CNB 7, SEB 3, Both | 9, CNB 7, SEB 3, Both | NGS | V2–V4 V6–V9 | Proteobacteria are the most abundant phylum followed by Firmicutes, Actinobacteria, and Bacteroidetes. The presence of the genus Ralstonia is associated with breast tissue. The relative abundance of Methylobacterium was different in certain patients. | [45] |
Biological Materials | Approach (Targeted/Untargeted) | Altered Metabolites and Metabolic Pathways | Ref. | |
---|---|---|---|---|
Cell Line | Tissue | |||
√ | GC–TOFMS (Targeted) | Increased beta-alanine, 2-hydroyglutarate, glutamate, xanthine, and decreased glutamine in ER− subtype compared to ER+ Beta-alanine has shown the most significant change between breast cancer ER− and ER+ | [55] | |
√ | LC-/MRM-MS GC-MS (Targeted and Untargeted) | Up-regulation of histidine, glutamine, tyrosine, creatine, phenylalanine, lactic acid, adonitol, glutamic acid, and downregulation of 3,7-cholest-5-ene. The study identified tryptophan, tyrosine, and creatine, in serum and tissue as potential markers for invasive ductal carcinoma (IDC). | [60] | |
√ | GC-MS | cytidine-5-monophosphate/pentadecanoic acid metabolic ratio was a significant discriminator between cancer and normal tissues | [62] | |
√ | NMR FT-ICR-MS | glutaminolysis is connected to pyrimidine ring synthesis in all cell types anaplerotic pyruvate carboxylation was activated in breast cancer versus primary cells | [70] | |
√ | LC-MS/MS (Targeted) | Glycine biosynthetic pathway was highly correlated with fast proliferating breast cancer cells | [71] | |
√ | √ | LC-MS, GC-MS (Targeted) | Higher level of aspartate in breast cancer tissues than adjacent non-tumor tissues, MCF-7 cell line than in MCF-10A cells | [72] |
√ | MALDI MSI (Targeted) | Adenosine diphosphate, adenosine monophosphate, adenosine triphosphate, aspartate, citrate, deoxycytidine diphosphate, fructose 1,6-bisphosphate, glutamate, glutathione, glutathione disulfide, guanosine diphosphate, N-acetylaspartate, NADH, UDP-glucose, DP-N-acetylglucosamine, UDP, UMP | [73] | |
√ | GC-TOF-MS (UPLC-MS) | Phospholipids, including PtdCho-s, phosphatidylethanolamines, phosphatidylinositol, sphingomyelin, triglycerides | [75,76] | |
√ | LC-ESI-MS/NMR (Targeted) | Up-regulation of choline, phosphocholine, glycerophosphocholine | [77] | |
√ | HR MAS MRS (Untargeted) | Up-regulation of phosphocholine, glycine, taurine, creatine, lactate, ascorbate, and downregulation of glucose | [78] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Al-Ansari, M.M.; AlMalki, R.H.; Dahabiyeh, L.A.; Abdel Rahman, A.M. Metabolomics-Microbiome Crosstalk in the Breast Cancer Microenvironment. Metabolites 2021, 11, 758. https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11110758
Al-Ansari MM, AlMalki RH, Dahabiyeh LA, Abdel Rahman AM. Metabolomics-Microbiome Crosstalk in the Breast Cancer Microenvironment. Metabolites. 2021; 11(11):758. https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11110758
Chicago/Turabian StyleAl-Ansari, Mysoon M., Reem H. AlMalki, Lina A. Dahabiyeh, and Anas M. Abdel Rahman. 2021. "Metabolomics-Microbiome Crosstalk in the Breast Cancer Microenvironment" Metabolites 11, no. 11: 758. https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11110758